SCHEMBL5480030

SCHEMBL5480030

COCCN(C)c1ccc2[nH]ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.46
SLC6A4 P31645 5/20 0.46
SLC6A3 Q01959 4/20 0.46
PIK3CA P42336 1/20 0.39
PRKCQ Q04759 2/20 0.39
PRKCD Q05655 2/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
MAOA P21397 1/20 0.39
AHR P35869 3/20 0.39
NR4A2 P43354 2/20 0.39
LTA4H P09960 2/20 0.39
CYP2A6 P11509 1/20 0.39
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3335239 0.75 AHR (0.50) SLC6A2SLC6A4SLC6A3MAOAAHR
SCHEMBL18562081 0.74 BRAF (0.41) MEN1KMT2AALOX15
SCHEMBL3612090 0.73 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3MAOACYP2A6
SCHEMBL8433227 0.72 TYR (0.44) SLC6A2SLC6A4SLC6A3MEN1POLB
SCHEMBL3836298 0.70 AHR (0.50) SLC6A2SLC6A4SLC6A3MAOAAHR
SCHEMBL1196073 0.70 LTA4H (0.58) MEN1POLBMAPK1KMT2AMAOA
SCHEMBL13967147 0.69 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3PRKCQPRKCD
SCHEMBL28131512 0.68 MAOA (0.49) SLC6A2SLC6A4SLC6A3MAOAUSP2
SCHEMBL4344348 0.68 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3MAOAAHR
SCHEMBL1814748 0.68 LTA4H (0.56) MAOANR4A2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 US disclosed
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 US disclosed
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 US disclosed
CN-1738814-A Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORP (US) 2006-02-22 CN disclosed
US-20060004011-A1 Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis MKI67, CDK4, PGF SLC6A2 3615/4885SLC6A4 3211/4885SLC6A3 3544/4885
US-20060004011-A1 Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis MKI67, VEGFA, FLT1 SLC6A2 3676/4885SLC6A4 3195/4885SLC6A3 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.